Citadel AI Launches AI Governance Tool for Pharmaceutical Industry at Ono Pharmaceutical, Supporting Safe and Secure Business Reform with Generative AI

Citadel AI Inc. (CEO: Yuki Kobayashi, hereinafter "Citadel AI"), a provider of AI governance tools that strengthen corporate management capabilities in the generative AI era, announces that Ono Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka; President: Juichi Takino, hereinafter "Ono Pharmaceutical") has fully adopted Citadel AI's AI governance tool "Citadel Lens" to enhance the safety and reliability of generative AI utilization in its internal operations.

◼︎ Background of Deployment in the Pharmaceutical Industry

The adoption of AI in companies is now spreading across various departments, from the front lines to management. While actively utilizing AI, balancing "offense and defense" – how to protect against its security and reputational risks – is extremely important.

Citadel AI provides Citadel Lens, an AI governance tool that realizes "trustworthy AI" that is safe and secure, and promotes AI utilization. Citadel Lens is a unique product that supports the entire lifecycle of generative AI, from risk assessment during the introduction phase to real-time guardrails during the operational phase.

Especially in the pharmaceutical industry, a life-related industry, the confidentiality and accuracy of information handled are extremely important. When introducing generative AI, risk management related to AI-generated response errors (hallucinations), bias, and information security becomes a major challenge.

In recent years, competition and speed in creating innovative drugs and developing technologies necessary for drug discovery have intensified. For pharmaceutical companies to continue contributing to society through the creation of pharmaceuticals on a global stage, it is urgent to promote business transformation through digital transformation (DX) and establish an environment for promoting the use of generative AI, such as formulating guidelines. Ono Pharmaceutical is one of the companies promoting advanced DX initiatives in the pharmaceutical industry, and has now fully implemented our system after evaluating the functions of Citadel Lens in the field of AI governance.

◼︎ Future Outlook

Citadel Lens is a tool that appropriately detects and controls risks (response quality risks, security risks) in the input and output of generative AI applications.

Through the implementation of Citadel Lens at Ono Pharmaceutical, Citadel will provide a continuous quality verification process for the generative AI (such as business chatbots) used company-wide by Ono Pharmaceutical. This will not only maintain and improve the accuracy of generative AI responses but also enable early detection and response to unexpected risks, supporting the creation of an environment where employees can use AI with peace of mind. In the future, we aim to strengthen AI governance as a platform supporting "offensive and defensive DX," with a view to applying AI governance to more advanced areas, including drug discovery research and pharmaceutical development processes.

Junichi Iseki, IT I&O Manager, Digital Technology Division, Ono Pharmaceutical Co., Ltd.

At our company, we consider the utilization of digital technologies, including generative AI, as a key to strengthening our competitiveness. As a company involved in healthcare and pharmaceuticals, we believe that ensuring the safety and reliability of digital technologies is important. With the introduction of Citadel Lens, we expect to be able to automate the AI risk assessment that previously required significant time and effort, and establish a system that can promote innovation with a sense of speed.